PART I Overview We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subse...
Q2 FY2026 — expected 2026-08-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012399 | EDGAR | 118K words |
| 2025-02-28 | 2024-12-31 | 0001558370-25-001889 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001558370-24-002181 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001558370-23-002613 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002543 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001558370-21-002121 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001558370-20-001896 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001558370-19-001698 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001558370-18-001923 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001628280-26-052533 | EDGAR | — |
| 2025-11-04 | 2025-09-30 | 0001104659-25-106264 | EDGAR | 74K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010302 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001558370-25-006765 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014532 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011101 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007076 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018291 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0001558370-23-012739 | EDGAR | — |
| 2023-05-02 | 2023-03-31 | 0001558370-23-007675 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016818 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001558370-22-011888 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001628280-26-052170 | EDGAR | — |
| 2026-04-03 | 0001628280-26-023606 | EDGAR | 1K words |
| 2026-03-26 | 0001628280-26-021414 | EDGAR | — |
| 2026-03-20 | 0001628280-26-019995 | EDGAR | — |
| 2026-03-16 | 0001628280-26-018211 | EDGAR | — |
| 2026-03-02 | 0001104659-26-021801 | EDGAR | — |
| 2026-02-26 | 0001628280-26-011987 | EDGAR | — |
| 2026-01-09 | 0001628280-26-001459 | EDGAR | — |
| 2025-12-19 | 0001104659-25-123108 | EDGAR | — |
| 2025-12-11 | 0001104659-25-120141 | EDGAR | — |
162 total filings indexed. 131 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649904 |
| Ticker | RYTM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.rhythmtx.com |
| Listed | 2017-10-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RYTM (~200 tokens, structured JSON with cryptographic provenance)